Saturday, Apr 4 2020 | Time 02:55 Hrs(IST)
  • COVID-19 death toll tops 6,500 in France
  • UK confirms 38,168 COVID-19 cases, Britons urged to stick to social distancing
  • COVID-19: Bangladesh to bring back stranded citizens once situation improves
  • Iraq's COVID-19 cases rise to 820
  • Thane: Medical professionals seek insurance cover from state govt
  • COVID-19 death toll reaches 284, total cases climb to 7,028 in Africa: Africa CDC
  • Eight new cases take Assam's COVID 19 tally to 24
  • MHA exempts shops of agricultural machinery, truck repair, Tea industry from lockdown
  • Somali army kills 10 al-Shabab militants in southern region
  • Ensure smooth harvesting, sowing operation with social distancing: Centre to States
  • MHA allocates Rs 11,092 Cr fund under SDRMF to mitigate lockdown impact
  • Japan to house COVID-19 patients in hotels as hospitals feel strain
  • Chinese man sentenced to 18 months in prison for obstructing COVID-19 prevention, treatment
Press Releases » Business Wire India

Vimta Labs Announces the Centre of Excellence for Bioassays at Confluence 2020

Vimta Labs Announces the Centre of Excellence for Bioassays at Confluence 2020
Dr. Huw Hughes delivering scientific talk at Confluence 2020 by Vimta Labs
Business Wire India

Leading Contract Research and Testing Organization, Vimta Labs has conducted Confluence - 2020, a knowledge sharing session to sensitize pharma industry about upcoming regulatory and scientific developments.

The theme of the event was development of large molecule drugs also called as biologics. Scientists and researchers from various parts of the globe have interacted with the participants about the developments in their respective areas of research.

Welcoming the participants to the event, Suresh Kumar, President of Vimta Labs said, “The last decade has seen a substantial shift in the focus of pharma industry from small molecules to large molecules. Biologics is changing the way doctors treat diseases and health conditions that have eluded us over the years & are now helping us improve the Quality of Life. This change is more pronounced in the case of cancer, autoimmune and infectious diseases.”

He also announced that, “With the increasing emphasis on large molecule drugs, we have established a dedicated state-of-the-art facility for biologics development. We are proud to announce that Vimta has set up a Centre of Excellence for Bioassays.”

Established in 1984, Vimta touches our daily lives with a wide range of testing and contract research solutions in health, pharma, food, water, consumer products, environment, agri and digital technology. The new Centre of Excellence for Bioassays will help pharma companies in furthering their research on large molecule drugs. It also has a long history of commissioning first-in-India solutions for Pharma industry such as Nitrosamine Impurity Profiling, Ultra Trace Analysis, Extractable & Leachables and Customer Specific Contract Labs.

Apart from developing new contract research solutions for the pharma industry, the company has also recently committed an investment of 100 crores in the Electrical & Electronics testing and certification area to cater to the country's requirements to become a manufacturing hub for Electrical & Electronic components and products.
More News
Pernod Ricard India Foundation and Akshay Patra, Feeding the Daily Wage Workers Amid Nationwide Lockdown

Pernod Ricard India Foundation and Akshay Patra, Feeding the Daily Wage Workers Amid Nationwide Lockdown

02 Apr 2020 | 6:15 PM

Pernod Ricard India Foundation has a long-standing partnership with The Akshaya Patra Foundation. We are now contributing 4000 meals a day, to Delhi Government’s drive to feed vulnerable migrants and daily wage workers.

see more..
Unimoni India appoints George Antony as Executive Vice–Chairman

Unimoni India appoints George Antony as Executive Vice–Chairman

02 Apr 2020 | 5:35 PM

Unimoni Financial Services has appointed V George Antony as Executive Vice-Chairman of Unimoni India.

see more..

VCCEdge Reports Decline in the Quantum of Funds as COVID-19 Spreads

01 Apr 2020 | 5:46 PM

Startup funding in India shows a decline in the quantum of funds in the month of March due to the coronavirus crisis. Venture Capital investors are now holding back their plan of startup fundings due to the fallout of economies in coping with the crisis.

see more..